Mounjaro vs. Ozempic: The Real Verdict, Price and All

Is Mounjaro actually better than Ozempic?

The most direct answer arrived in May 2025, when SURMOUNT-5 put the two molecules through the same protocol instead of comparing separate trials run years apart. Adults with obesity, none of them living with diabetes, were randomized to the maximum tolerated dose of either drug for 72 weeks and measured side by side. Tirzepatide, the active ingredient in Mounjaro, produced a mean weight change of about 20% of starting body weight. Semaglutide, Ozempic's active ingredient, produced about 14%. Waist circumference fell further on tirzepatide too, and a meaningfully larger share of that group crossed every major weight-loss threshold researchers track, from 10% up through 25%.

One detail is worth knowing before you treat that gap as a settled verdict on the two brands specifically: the trial titrated semaglutide to a maximum tolerated 1.7 or 2.4mg, above the 2mg ceiling that's actually approved for Ozempic, while tirzepatide's 15mg matched Mounjaro's own approved maximum. Semaglutide has since climbed higher again — the FDA approved a 7.2mg Wegovy dose in March 2026 that reached about 20.7% average weight loss in a separate trial of its own — but neither of those doses is what an Ozempic prescription gives you. That's the nuance that tends to get lost when SURMOUNT-5 is cited as a blanket verdict between the two diabetes brands.

Those numbers are trial averages, not a promise for any one person. Results vary with dose, adherence, diet, and physiology. But on the narrow question of average effect size in a direct comparison, tirzepatide currently holds the stronger evidence.

What's the real difference between Ozempic and Mounjaro?

Semaglutide acts on a single target, the GLP-1 receptor, slowing digestion and quieting appetite signals in the brain. Tirzepatide does that too, but adds a second receptor, GIP, that appears to compound the effect on appetite and on how the body handles blood sugar. That dual action is the leading explanation for tirzepatide's edge above, though exactly how much comes from the extra receptor versus the specific doses tested is still being studied. For the deeper mechanism-level breakdown, semaglutide vs. tirzepatide covers that ground in full — this page stays focused on the Mounjaro-versus-Ozempic decision specifically, including the indication question that comparison doesn't need to cover.

Ozempic and Mounjaro are also each one half of a two-brand story. Semaglutide is sold as Ozempic for diabetes and, at a higher dose, as Wegovy for obesity. Tirzepatide is sold as Mounjaro for diabetes and, at the same top dose, as Zepbound for obesity. Same molecules, same manufacturers, different FDA approvals attached to different brand names — and that distinction drives almost everything in the next section.

Mounjaro and Ozempic are both diabetes drugs — does that change things if you want them for weight loss?

It changes almost everything about cost and coverage, even though it changes nothing about how the drug works in your body. Mounjaro was approved in May 2022, and Ozempic back in 2017, both specifically to improve blood sugar control in adults with type 2 diabetes. Neither has ever picked up a weight-management indication — that belongs to their sister brands, Zepbound and Wegovy. A prescriber can still write a Mounjaro or Ozempic prescription off-label for weight loss, and that's a legal, fairly common practice in obesity medicine. What changes is everything downstream of the prescription itself.

Insurance pays by indication, not by molecule. A plan that covers Mounjaro for a documented type-2-diabetes diagnosis can, and often does, deny the identical drug when the only diagnosis on the chart is obesity. Medicare is more absolute about it: federal law bars Part D from covering a drug prescribed solely for weight loss, so Mounjaro or Ozempic used off-label gets zero Medicare coverage no matter how the appeal is worded. The manufacturer savings cards follow the same logic — both require a prescription that matches the drug's FDA-approved label, so a chart that reads "weight loss" rather than "type 2 diabetes" can disqualify you from the $25 tier even if you happen to have diabetes too.

If weight management is genuinely the primary goal, the cleaner path is usually asking your provider about Zepbound or Wegovy directly — same molecules, an on-label indication, and access to insurance coverage and savings programs actually built around that use.

Ozempic vs Mounjaro: which costs less — compounded, brand, or insured?

Ozempic wins on price at nearly every tier we could verify, though the compounded and insured tiers narrow the gap to almost nothing. The table above lines up the comparable options side by side; the sections below walk through what's actually behind each number.

Compounded semaglutide vs. compounded tirzepatide

The cheapest verified compounded options come from two different providers. Curex holds the lowest all-in price for tirzepatide, around $199 a month with medication, consult and shipping bundled and no separate membership fee. Fridays holds the lowest verified price for compounded semaglutide, running $150 to $249 a month depending on plan length. Both figures are starter-dose rates — ask for the maintenance-dose ladder in writing before you enroll, since several competing programs quietly raise the price as you titrate up.

Mounjaro vs. Ozempic brand pricing, no insurance

This is where the gap opens widest. Eli Lilly has no separate self-pay vial program for the Mounjaro brand itself, so if you're uninsured, you're paying close to the retail list price — a bit over $1,080 a month, with only a modest GoodRx discount available on top. Ozempic, by contrast, has Novo Nordisk's own cash-pay program: $199 a month for the first two starter-dose fills, then $349 a month at the maintenance dose or $499 at the highest pen strength. At retail, an uninsured year of either drug runs into five figures; on NovoCare's self-pay ladder, Ozempic's annual cost lands closer to $4,200.

With insurance and the manufacturer savings card

Here the two converge. If your commercial plan covers the drug for type 2 diabetes and the prescription matches that label, both the Mounjaro Savings Card and the NovoCare Savings Card can bring your monthly cost down to around $25. Government insurance — Medicare, Medicaid, TRICARE — is excluded from both cards entirely, no exceptions.

Does insurance cover Mounjaro or Ozempic more easily?

For a documented type-2-diabetes diagnosis, coverage for either drug is common but rarely automatic — prior authorization is the norm, typically requiring your prescriber to document the diagnosis, sometimes an A1C reading, and occasionally a trial of a cheaper diabetes medication first. Employer plan design matters more than the drug itself: larger employers are considerably more likely to include either drug on formulary than small-group plans, and that can change year to year with a plan renewal.

For weight loss specifically, the denial reality is blunt. Most commercial plans will approve Mounjaro or Ozempic for a T2D diagnosis and deny the same drug outright when the chart shows only obesity or overweight as the reason. Some prescribers work around this by billing under a genuine, secondary T2D or prediabetes diagnosis where one exists, but that only works if the diagnosis is real and documented, not added to game a coverage rule. Practically: check your plan's own formulary and prior-authorization criteria before assuming either brand is the easier path, and don't be surprised if the answer is different for the same drug depending on which diagnosis your prescriber submits.

Side effects — is one easier to tolerate?

Both drugs cause the same family of gastrointestinal side effects, for the same underlying reason: slowing digestion is the mechanism, not a side issue of it. Nausea, vomiting, diarrhea, and constipation are the most commonly reported problems with both, clustering hardest in the weeks after a dose increase before typically easing.

In SURMOUNT-5, gastrointestinal side effects severe enough to stop treatment happened more often on semaglutide than tirzepatide, about 5.6% versus 2.7% of participants. Some separate trial and real-world data suggest a difference in which symptom shows up more: semaglutide skewing slightly toward nausea and constipation, tirzepatide slightly toward looser stools. Neither pattern is universal, and plenty of women tolerate one drug better than the other for reasons that don't show up cleanly in trial averages.

Which one is right for you? Verdict by profile

• You have type 2 diabetes and insurance that covers one of them: let coverage decide — fighting a formulary for the uncovered drug rarely beats using the one your plan already pays for at $25/mo.
• You want the strongest average result and cost is secondary: Mounjaro's head-to-head edge in SURMOUNT-5 is the best evidence either drug has for a bigger average outcome — worth the modest cost premium if the result matters more to you than the price gap.
• Budget is the deciding factor and you're paying cash: Ozempic is cheaper at nearly every tier, brand or compounded, and for many women the difference between a 14% and a 20% average result matters less than a few hundred dollars a month.
• Weight loss, not diabetes, is your actual goal: neither Mounjaro nor Ozempic carries that FDA indication — ask your provider about Zepbound or Wegovy instead, since insurance and savings-card rules are built around that use, not this one.
• You've struggled with nausea on a GLP-1 before: the trial-level discontinuation data gives tirzepatide a slight edge on tolerability, though this varies person to person and isn't a guarantee.

Can you switch from Ozempic to Mounjaro (or the reverse)?

Yes, clinicians make this switch routinely when a plateau shows up or side effects become hard to live with. There's no FDA-established dose equivalency between semaglutide and tirzepatide, so a switch isn't a matter of converting your current dose to a matching one on the other drug. In practice, most prescribers restart the new drug at its lowest introductory level rather than matching where you left off, timing the transition around each drug's weekly dosing schedule so there isn't an overlap. How that's managed — timing, monitoring, what to expect in the first few weeks — is worth working through directly with whoever is prescribing, since it varies by provider and by how you responded to the first drug.

Is compounded tirzepatide or compounded semaglutide the safer, more legitimate choice?

Neither molecule has a broad compounding allowance anymore. Both were compounded at scale during their respective FDA shortage designations, and both shortages have since been declared resolved — tirzepatide in December 2024, semaglutide in February 2025 — with enforcement discretion for 503A pharmacies and 503B outsourcing facilities winding down through early 2025. What remains for both drugs is a narrower 503A individual-patient pathway: a compounding pharmacy preparing the medication for a specific patient with a documented clinical reason the FDA-approved version won't work for them. Cost savings alone isn't a qualifying reason under current FDA guidance, even though cost is the reason most patients are drawn to it.

There's a pending regulatory question layered on top: the FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulk drug substances list in April 2026, a step that would formalize what's already happened in practice; that comment period was reportedly extended into the summer, with no final rule issued as of this writing. Separately, both manufacturers have gone after telehealth compounders directly — Eli Lilly sued several in 2025, and Novo Nordisk filed more than a dozen suits in August 2025 plus a patent case against Hims & Hers in early 2026, generally over marketing claims and, in a few cases, patent or corporate-practice-of-medicine disputes rather than allegations that the pharmacies aren't dispensing real medication. As of mid-2026 that litigation is ongoing and unresolved, which is itself worth weighing before you enroll anywhere.

In practical terms, the legitimacy question isn't really "tirzepatide vs. semaglutide" — it's about the individual pharmacy and provider on either side of the transaction. Look for PCAB-accredited pharmacies, clear sourcing, and a provider willing to explain how they document medical necessity for either drug. That standard applies equally to both molecules.

Mounjaro vs Ozempic for perimenopause and menopause weight gain

The weight shift that shows up in perimenopause has a specific hormonal driver: falling estrogen worsens insulin resistance and pushes fat storage toward the abdomen, on top of whatever else is going on in a woman's life at 40-plus. Both drugs act on pathways relevant to that shift, improving insulin sensitivity and reducing appetite signaling, which is part of why obesity-medicine physicians increasingly view GLP-1 medications as reasonably well matched to the perimenopausal metabolic environment generally.

No trial has directly compared Mounjaro and Ozempic specifically in a perimenopausal or postmenopausal population, so there isn't a menopause-specific verdict to report between them. For most women in this stage without a T2D diagnosis, the more relevant real-world question usually isn't Mounjaro versus Ozempic at all — it's whether the on-label weight-management brands, or a compounded option, fit their situation and budget better than either diabetes-branded drug used off-label.